Last reviewed · How we verify

PXT3003 dose 1 — Competitive Intelligence Brief

PXT3003 dose 1 (PXT3003 dose 1) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Fixed-dose combination / Immunomodulator. Area: Neurology / Rare Genetic Disorders.

phase 3 Fixed-dose combination / Immunomodulator Multiple targets (baclofen: GABA-B receptor; naltrexone: opioid receptors; sorbitol: osmotic agent) Neurology / Rare Genetic Disorders Small molecule Live · refreshed every 30 min

Target snapshot

PXT3003 dose 1 (PXT3003 dose 1) — Pharnext S.C.A.. PXT3003 is a fixed-dose combination of three active pharmaceutical ingredients that work synergistically to reduce neuroinflammation and promote nerve regeneration in peripheral neuropathies.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
PXT3003 dose 1 TARGET PXT3003 dose 1 Pharnext S.C.A. phase 3 Fixed-dose combination / Immunomodulator Multiple targets (baclofen: GABA-B receptor; naltrexone: opioid receptors; sorbitol: osmotic agent)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Fixed-dose combination / Immunomodulator class)

  1. Pharnext S.C.A. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). PXT3003 dose 1 — Competitive Intelligence Brief. https://druglandscape.com/ci/pxt3003-dose-1. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: